GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TransMedics Group Inc (NAS:TMDX) » Definitions » Cash Flow from Investing

TransMedics Group (TransMedics Group) Cash Flow from Investing : $-237.2 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is TransMedics Group Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, TransMedics Group spent $44.2 Mil on purchasing property, plant, equipment. It gained $0.0 Mil from selling property, plant, and equipment. It spent $0.0 Mil on purchasing business. It gained $0.0 Mil from selling business. It spent $0.0 Mil on purchasing investments. It gained $0.0 Mil from selling investments. It paid $0.0Mil for net Intangibles purchase and sale. And it paid $0.0 Mil for other investing activities. In all, TransMedics Group spent $44.2 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


TransMedics Group Cash Flow from Investing Historical Data

The historical data trend for TransMedics Group's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TransMedics Group Cash Flow from Investing Chart

TransMedics Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial -60.50 -41.60 29.27 54.51 -193.95

TransMedics Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.93 -1.38 -149.83 -41.82 -44.17

TransMedics Group Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

TransMedics Group's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

TransMedics Group's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-237.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TransMedics Group  (NAS:TMDX) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

TransMedics Group's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $-44.2 Mil. It means TransMedics Group spent $44.2 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

TransMedics Group's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.0 Mil. It means TransMedics Group gained $0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

TransMedics Group's purchase of business for the three months ended in Mar. 2024 was $0.0 Mil. It means TransMedics Group spent $0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

TransMedics Group's sale of business for the three months ended in Mar. 2024 was $0.0 Mil. It means TransMedics Group gained $0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

TransMedics Group's purchase of investment for the three months ended in Mar. 2024 was $0.0 Mil. It means TransMedics Group spent {stock_data.stock.currency_symbol}}0.0 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

TransMedics Group's sale of investment for the three months ended in Mar. 2024 was $0.0 Mil. It means TransMedics Group gained $0.0 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

TransMedics Group's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.0 Mil. It means TransMedics Group paid $0.0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

TransMedics Group's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.0 Mil. It means TransMedics Group paid $0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

TransMedics Group's cash from other investing activities for the three months ended in Mar. 2024 was $0.0 Mil. It means TransMedics Group paid $0.0 Mil for other investing activities.


TransMedics Group Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of TransMedics Group's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


TransMedics Group (TransMedics Group) Business Description

Traded in Other Exchanges
Address
200 Minuteman Road, Andover, MA, USA, 01810
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body.
Executives
Tamer I Khayal officer: Chief Commercial Officer TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810
Miriam Provost officer: VP of US Regulatory & FDA Rel. 2000 MINUTEMAN ROAD, ANDOVER MA 01810
Waleed H Hassanein director, officer: President & CEO TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810
James R Tobin director C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Stephen Gordon officer: Chief Financial Officer 200 MINUTEMAN ROAD, ANDOVER MA 01810
David Weill director 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Anil P. Ranganath officer: See Remarks C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Edward M Basile director 200 MINUTEMAN ROAD, ANDOVER MA 01810
John F Carey officer: VP of Operations 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Nicholas Corcoran officer: See Remarks C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Laura Damme officer: VP, Clinical Affairs C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Stephanie Lovell director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Kania Edwin M Jr director
Rakesh P. Godhani officer: Chief Digital Officer C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
John F Sullivan officer: VP of Quality & Engineering 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810